ORKA

Business Context and Reporting Period

This summary covers the Form 10-Q filed by Nuvelo, Inc. (not Oruka Therapeutics) for the quarterly period ended September 30, 2004. Nuvelo is a biopharmaceutical company focused on the discovery and development of therapeutics for acute cardiovascular indications and cancer. The company operates through two segments: Nuvelo (therapeutics) and Callida Genomics (sequencing technology). As of the filing date, the company had an accumulated deficit of $243.1 million and was not profitable.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported $70.7 million in total cash, cash equivalents, and short-term investments.

Material Changes vs. Prior Period

• Revenue Growth: Contract revenues increased to $0.7 million for the quarter (from $0.3 million in Q3 2003) and $2.2 million for the nine-month period (from $1.9 million in 2003). This was driven primarily by increased grant revenue from the National Institute of Standards and Technology (NIST) and the National Institute of Health (NIH).
• Operating Expenses: Research and Development (R&D) expenses rose to $8.7 million for the quarter and $34.8 million for the nine months. The nine-month increase was largely due to $6.8 million in license fees for new agreements with Archemix and Dendreon, and increased clinical trial costs. General and Administrative (G&A) expenses decreased significantly to $6.7 million for the nine months (from $14.4 million in 2003) due to lease termination costs in the prior year and savings from shutting down Variagenics operations.
• Liquidity Position: Cash and short-term investments increased from $34.2 million at year-end 2003 to $70.7 million at September 30, 2004. This increase was primarily due to a public offering in March 2004 that raised approximately $69.5 million net of fees.
• Debt Structure: In August 2004, the company entered a new Loan and Security Agreement with Silicon Valley Bank, providing a $4.0 million revolving credit line and a $6.0 million term loan facility. An initial drawdown of $2.6 million was used to repay a prior obligation.

Guidance, Outlook, and Risks

• Product Pipeline: The company is advancing three clinical-stage candidates: alfimeprase (Phase 3 expected Q1 2005 for peripheral arterial occlusion), rNAPc2 (Phase 2a for acute coronary syndromes), and ARC183 (Phase 1 initiated August 2004 for CABG surgery).
• Collaboration Changes: In late October/early November 2004 (post-period end), Nuvelo converted its collaboration with Amgen regarding alfimeprase into a licensing arrangement. Nuvelo paid $8.5 million to settle manufacturing costs and secure exclusive worldwide rights. A $5.0 million milestone payment is due upon the first patient dosing in the Phase 3 trial (expected Q1 2005).
• Future Cash Needs: Management expects to incur significant operating losses for the foreseeable future. They anticipate expensing $12.7 million in drug manufacturing costs within the next twelve months. While they believe current reserves are adequate through 2005, they may need to raise additional capital.
• Risks: Key risks include the uncertainty of clinical trial results, the potential failure to obtain FDA approval, reliance on third-party manufacturers (specifically the transition of alfimeprase manufacturing from Amgen), and the high cost of development. The company also faces potential litigation regarding stock options granted to former employees and a securities class action lawsuit inherited from the Variagenics merger.

Investor Verification Checklist

• Manufacturing Transition: Verify the status of the transition of alfimeprase manufacturing from Amgen to a new contract manufacturer, as supply chain disruption could delay Phase 3 trials.
• Milestone Obligations: Confirm the timing and funding availability for the $5.0 million milestone payment to Amgen due in Q1 2005 and potential future milestones totaling up to $84.5 million across all agreements.
• Cash Burn Rate: Monitor the rate of cash consumption against the $70.7 million liquidity position to ensure sufficiency through 2005 without immediate dilution.
• Regulatory Status: Track the FDA's response to the Investigational New Drug (IND) application for ARC183 and the design of the Phase 3 trial for alfimeprase.
• Legal Contingencies: Review updates on the Variagenics securities class action settlement and the dispute regarding stock options with former employees.